The lifetime risk of an unexpected and sudden death from a cardiovascular cause in the absence of pre-existing heart disease-;known as sudden cardiac death-;is more than 4 times higher for people with schizophrenia than it is for the general population, indicates Danish research published online in the journal Heart.
GSK and CureVac restructure mRNA vaccine development deal
The vaccines utilise CureVac’s second-generation mRNA backbone. Credit: Gorodenkoff/Shutterstock. GSK and Curevac have announced the restructuring of their existing partnership into a new licensing agreement
July 3, 2024